{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:44:31Z","timestamp":1774089871264,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","award":["8-688\/A-688\/2019"],"award-info":[{"award-number":["8-688\/A-688\/2019"]}],"id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02057-y","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:02:27Z","timestamp":1685624547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)"],"prefix":"10.1007","volume":"40","author":[{"given":"S.","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chitikela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0205-8559","authenticated-orcid":false,"given":"P. S.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"2057_CR1","unstructured":"GLOBOCAN 2020: New Global Cancer Data|UICC. https:\/\/www.uicc.org\/news\/globocan-2020-new-global-cancer-data. Accessed 8 Dec 2022"},{"issue":"Supplement 1","key":"2057_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.13-S1-5","volume":"13","author":"S Ramalingam","year":"2008","unstructured":"Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(Supplement 1):5\u201313.","journal-title":"Oncologist"},{"issue":"1","key":"2057_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7314\/APJCP.2013.14.1.489","volume":"14","author":"PS Malik","year":"2013","unstructured":"Malik PS, Sharma MC, Mohanti BK, Shukla NK, Deo SVS, Mohan A, et al. Clinico-pathological profile of lung cancer at aiims: a changing paradigm in India. Asian Pac J Cancer Prev. 2013;14(1):489\u201394.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"16_suppl","key":"2057_CR4","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.1200\/JCO.2022.40.16_suppl.9012","volume":"40","author":"M Ravikrishna","year":"2022","unstructured":"Ravikrishna M, Abraham G, Patil VM, Bhattacharjee A, Noronha V, Menon NS, et al. Checkpoint inhibitor accessibility in 15,000+ Indian patients. JCO. 2022;40(16_suppl):9012.","journal-title":"JCO"},{"key":"2057_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/EDBK_10033","volume":"42","author":"R Jalali","year":"2022","unstructured":"Jalali R, Nogueira-Rodrigues A, Das A, Sirohi B, Panda PK. Drug development in low- and middle-income countries: opportunity or exploitation? Am Soc Clin Oncol Educ Book. 2022;42:3\u201310.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2057_CR6","doi-asserted-by":"publisher","first-page":"e0191129","DOI":"10.1371\/journal.pone.0191129","volume":"13","author":"MC Chuang","year":"2018","unstructured":"Chuang MC, Yang YH, Tsai YH, Hsieh MJ, Lin YC, Lin CK, et al. Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: a population-based retrospective cohort study. PLoS ONE. 2018;13(1):e0191129.","journal-title":"PLoS ONE"},{"issue":"13","key":"2057_CR7","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.7150\/jca.19750","volume":"8","author":"X Cao","year":"2017","unstructured":"Cao X, Wen ZS, Wang XD, Li Y, Liu KY, Wang X. The clinical effect of metformin on the survival of lung cancer patients with diabetes: a comprehensive systematic review and meta-analysis of retrospective studies. J Cancer. 2017;8(13):2532\u201341.","journal-title":"J Cancer"},{"issue":"12","key":"2057_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cancers9050045","volume":"9","author":"M Yousef","year":"2017","unstructured":"Yousef M, Tsiani E. Metformin in lung cancer: review of in vitro and in vivo animal studies. Cancers. 2017;9(12):45.","journal-title":"Cancers"},{"issue":"7","key":"2057_CR9","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.7314\/APJCP.2013.14.7.4033","volume":"14","author":"D Han","year":"2013","unstructured":"Han D, Li SJ, Zhu YT, Liu L, Li MX. LKB1\/AMPK\/mTOR Signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev. 2013;14(7):4033\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7511","key":"2057_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","journal-title":"Nature"},{"issue":"35","key":"2057_CR11","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1038\/onc.2011.98","volume":"30","author":"RK Gill","year":"2011","unstructured":"Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS, et al. Frequent homozygous deletion of the LKB1\/STK11 gene in non-small cell lung cancer. Oncogene. 2011;30(35):3784\u201391.","journal-title":"Oncogene"},{"issue":"7216","key":"2057_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","volume":"455","author":"L Ding","year":"2008","unstructured":"Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069\u201375.","journal-title":"Nature"},{"issue":"2","key":"2057_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2012.12.008","volume":"23","author":"DB Shackelford","year":"2013","unstructured":"Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23(2):143\u201358.","journal-title":"Cancer Cell"},{"issue":"14","key":"2057_CR14","doi-asserted-by":"publisher","first-page":"23831","DOI":"10.18632\/oncotarget.6379","volume":"8","author":"N P\u00e9cuchet","year":"2015","unstructured":"P\u00e9cuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K, et al. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget. 2015;8(14):23831\u201340.","journal-title":"Oncotarget"},{"issue":"7","key":"2057_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"5","key":"2057_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Can Res. 2016;76(5):999\u20131008.","journal-title":"Can Res"},{"issue":"8","key":"2057_CR17","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cam4.1133","volume":"6","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Feng X, Li T, Yi E, Li Y. Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro. Cancer Med. 2017;6(8):1965\u201375.","journal-title":"Cancer Med"},{"issue":"6","key":"2057_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10637-017-0511-7","volume":"35","author":"AB Parikh","year":"2017","unstructured":"Parikh AB, Kozuch P, Rohs N, Becker DJ, Levy BP. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. Invest New Drugs. 2017;35(6):813\u20139.","journal-title":"Invest New Drugs"},{"issue":"7","key":"2057_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1634\/theoncologist.2017-0465","volume":"23","author":"KA Marrone","year":"2018","unstructured":"Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL, et al. A randomized phase II study of metformin plus paclitaxel\/carboplatin\/bevacizumab in patients with chemotherapy-Na\u00efve advanced or metastatic nonsquamous non-small cell lung cancer. Oncologist. 2018;23(7):859\u201365.","journal-title":"Oncologist"},{"key":"2057_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100150","volume":"20","author":"AB Parikh","year":"2019","unstructured":"Parikh AB, Marrone KA, Becker DJ, Brahmer JR, Ettinger DS, Levy BP. A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Treat Res Commun. 2019;20: 100150.","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"2057_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000514577","volume":"99","author":"A Yadav","year":"2021","unstructured":"Yadav A, Malik PS, Khurana S, Jain D, Vishnubhatla S, Yadav M, et al. An open-label randomized controlled trial comparing the efficacy and safety of pemetrexed-carboplatin versus (Weekly) paclitaxel-carboplatin as first-line chemotherapy in advanced non-squamous non-small cell lung cancer. Oncology. 2021;99(6):389\u201396.","journal-title":"Oncology"},{"issue":"14","key":"2057_CR22","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer. JCO. 2020;38(14):1505\u201317.","journal-title":"JCO"},{"issue":"21","key":"2057_CR23","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543\u201351.","journal-title":"J Clin Oncol"},{"issue":"22","key":"2057_CR24","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"4","key":"2057_CR25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/bjc.2015.261","volume":"113","author":"M Momcilovic","year":"2015","unstructured":"Momcilovic M, Shackelford DB. Targeting LKB1 in cancer\u2014exposing and exploiting vulnerabilities. Br J Cancer. 2015;113(4):574\u201384.","journal-title":"Br J Cancer"},{"key":"2057_CR26","unstructured":"Garassino M. Exploiting Metformin Plus\/Minus Cyclic Fasting Mimicking Diet (FMD) to Improve the Efficacy of First Line Chemo-immunotherapy in Advanced LKB1-inactive Lung Adenocarcinoma [Internet]. clinicaltrials.gov; 2020. Report No.: NCT03709147. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03709147. Accessed 18 Feb 2021"},{"key":"2057_CR27","unstructured":"Rodr\u00edguez OGA. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone for Patients With Advanced Non-small Cell Lung Cancer and EGFR Mutations: Phase 3 Randomized Clinical Trial [Internet]. clinicaltrials.gov; 2022. Report No.: NCT05445791. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05445791. Accessed 27 Mar 2023"},{"issue":"1","key":"2057_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.21037\/tcr.2019.11.09","volume":"9","author":"H Wang","year":"2020","unstructured":"Wang H, Yang X, Sun Y, Li Y, Dong Y, Shan D, et al. Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer. Trans Cancer Res. 2020;9(1):372\u201381.","journal-title":"Trans Cancer Res"},{"issue":"10","key":"2057_CR29","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","volume":"20","author":"L Li","year":"2014","unstructured":"Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20(10):2714\u201326.","journal-title":"Clin Cancer Res"},{"key":"2057_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01605","author":"L Li","year":"2020","unstructured":"Li L, Wang T, Hu M, Zhang Y, Chen H, Xu L. Metformin Overcomes acquired resistance to EGFR TKIs in EGFR-mutant lung cancer via AMPK\/ERK\/NF-\u03baB signaling pathway. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01605.","journal-title":"Front Oncol"},{"key":"2057_CR31","doi-asserted-by":"crossref","unstructured":"Hung MS, Chuang MC, Tsai YH, Yang YH. Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy&gt; European Respiratory Journal [Internet]. 2018 https:\/\/erj.ersjournals.com\/content\/52\/suppl_62\/PA2856. Accessed 20 Feb 2021","DOI":"10.1183\/13993003.congress-2018.PA2856"},{"key":"2057_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2553","volume":"5","author":"O Arrieta","year":"2019","unstructured":"Arrieta O, Barr\u00f3n F, Padilla M\u00c1S, Avil\u00e9s-Salas A, Ram\u00edrez-Tirado LA, Arguelles Jim\u00e9nez MJ, et al. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5: e192553.","journal-title":"JAMA Oncol"},{"key":"2057_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.639016","author":"X Luo","year":"2021","unstructured":"Luo X, Chen X, Wang L, Yang B, Cai S. Metformin adjunct with antineoplastic agents for the treatment of lung cancer: a meta-analysis of randomized controlled trials and observational cohort studies. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.639016.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2057_CR34","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41416-020-01186-9","volume":"124","author":"S Brancher","year":"2021","unstructured":"Brancher S, St\u00f8er NC, Weiderpass E, Damhuis RAM, Johannesen TB, Botteri E, et al. Metformin use and lung cancer survival: a population-based study in Norway. Br J Cancer. 2021;124(5):1018\u201325.","journal-title":"Br J Cancer"},{"issue":"8","key":"2057_CR35","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/biom11081252","volume":"11","author":"JL Wang","year":"2021","unstructured":"Wang JL, Tsai YT, Lin CH, Cidem A, Staniczek T, Chang GRL, et al. Benefits of metformin combined with pemetrexed-based platinum doublets as a first-line therapy for advanced lung adenocarcinoma patients with diabetes. Biomolecules. 2021;11(8):1252.","journal-title":"Biomolecules"},{"key":"2057_CR36","unstructured":"Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy|Elsevier Enhanced Reader [Internet]. https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S2211124720308299?token=3A2C0DC0BFF9528B38B26F5F68C75C9AD7FC97AF280BC09D488E99952EC4612D828AA34556CBD43C00B6B68D674D08E4. Accessed 15 Feb 2021"},{"key":"2057_CR37","unstructured":"Chae YK. Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1\/PD-L1 Inhibitors [Internet]. clinicaltrials.gov; 2020. Report No.: results\/NCT03048500. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03048500. Accessed 18 Feb 2021"},{"key":"2057_CR38","unstructured":"Tianjin Medical University Cancer Institute and Hospital. An Open-Label Single-Arm Phase II Study to Evaluate Efficacy and Safety of Sintilimab Combined With Metformin Hydrochloride in Patients With Advanced Non-small Cell Lung Cancer Refractory to First-Line Treatment [Internet]. clinicaltrials.gov; 2019. Report No.: NCT03874000. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03874000. Accessed 18 Feb 2021"},{"issue":"22","key":"2057_CR39","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.4161\/cc.26461","volume":"12","author":"C Marini","year":"2013","unstructured":"Marini C, Salani B, Massollo M, Amaro A, Esposito AI, Orengo AM, et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle. 2013;12(22):3490\u20139.","journal-title":"Cell Cycle"},{"issue":"3","key":"2057_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4329\/wjr.v7.i3.57","volume":"7","author":"S Capitanio","year":"2015","unstructured":"Capitanio S, Marini C, Sambuceti G, Morbelli S. Metformin and cancer: technical and clinical implications for FDG-PET imaging. World J Radiol. 2015;7(3):57\u201360.","journal-title":"World J Radiol"},{"issue":"2","key":"2057_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1148\/radiol.2018180078","volume":"289","author":"R Hamidizadeh","year":"2018","unstructured":"Hamidizadeh R, Eftekhari A, Wiley EA, Wilson D, Alden T, B\u00e9nard F. Metformin discontinuation prior to FDG PET\/CT: a randomized controlled study to compare 24- and 48-hour bowel activity. Radiology. 2018;289(2):418\u201325.","journal-title":"Radiology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02057-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T21:17:16Z","timestamp":1687900636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02057-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee of All India Institute of Medical Sciences, New Delhi (IEC PG-63\/23.01.2019, OT-09\/23.04.2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"192"}}